Summit Therapeutics Inc.
SMMT
$26.20
$0.190.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -361.42% | -107.50% | 64.01% | 67.09% | 72.95% |
| Total Depreciation and Amortization | -4.59% | -35.56% | -55.05% | -87.30% | -92.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,067.93% | 241.91% | -88.18% | -89.11% | -91.89% |
| Change in Net Operating Assets | 17.80% | 31.64% | 3,098.45% | 702.92% | 211.46% |
| Cash from Operations | -112.20% | -84.66% | -85.13% | -116.64% | -113.01% |
| Capital Expenditure | -304.92% | -605.06% | -8.59% | -9.48% | -183.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 332.74% | -183.81% | 65.09% | 64.82% | 80.93% |
| Cash from Investing | 332.11% | -184.37% | 65.06% | 64.79% | 80.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -305.09% | -205.84% | 100.00% |
| Issuance of Common Stock | 39.92% | 6,539.74% | 328.87% | 362.07% | 0.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,306.82% | 100.00% |
| Cash from Financing | -8.08% | 5,540.71% | 340.66% | -31.52% | -69.31% |
| Foreign Exchange rate Adjustments | 34.62% | -84.40% | -102.15% | -81.36% | -72.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,116.44% | 1,705.40% | 105.85% | 171.61% | 12.20% |